Skip to main content

Advertisement

SpringerLink
Log in

Long-term efficacy of 90Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

The aim of this study was to analyze the outcomes of 37 follicular lymphoma (FL) patients treated with 90ytrium ibritumomab tiuxetan (90Y-IT), outside of clinical trial, according to protocol ISCRTN36210045, after ≥5 years follow-up to February 2014. Health-related quality of life (HRQoL) was evaluated with the SF-36, Spanish version, and compared with the general population of Spain. Patients had a mean age of 61.9 (range, 30–85) years and included 18 males. FLIPI, low: 25 (67.6 %), intermedium 9 (24.3 %), and low 3 (8.1 %). Previous therapy schedules >2: 48.6 % The median follow-up was 66 months, mean Time to Relapse (TTR) 71.3 months (58.8–83.8) median not reached. Thirty-four patients achieved complete response (91.8 %), and three no response. Mean overall survival: 82.3 months (71.6–92.9). Four patients presented with concomitant tumors (colon, breast, prostate, lung) after radioimmunotherapy, and three developed second primary neoplasms (esophagus, renal, and myelodysplastic syndrome in a relapsed patient who received fludarabine). Four of 10 deaths were related to lymphoma progression. Hematological toxicities were mild and easily managed. No patients required hospitalization. Negative scores were obtained in the physical and emotional roles items; however, the perception of general health and vitality were better than in the general population, with the best outcomes in non-relapsed patients. Radioimmunotherapy with 90Y-IT was safe and effective as long-term therapy in patients with FL. Early use of radioimmunotherapy could offer good, sustained responses with low toxicity over the long term and acceptable HRQoL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Leukemia and Lymphoma Society. Facts 2012. Statistics Review. (2012) http://www.lls.org/content/nationalcontent/resourcecenter/freeeducationmterial/generalcancer/pdf/facts.pdf . Accessed 22 April 2014

  2. The Non-Hodgkin’s Lymphoma Classification Project (1997) A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 89:3909

    Google Scholar 

  3. Hoffman R, Furie B, Benz EJ, McGlave P, Silberstein LE, Shattil S (2009) Basic principles and practice of hematology, 5th edn. ED Elsevier, Amsterdam

    Google Scholar 

  4. Mac Manus MP, Hoppe RT (1996) Is radiotherapy curative for stage I and II lowgrade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol 14:1282–1290

    CAS  PubMed  Google Scholar 

  5. Dave SS, Wright G, Tan B et al (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351:2159

    Article  CAS  PubMed  Google Scholar 

  6. Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M. Watchful waiting in low–tumor burden follicular lymphoma in the rituximab era: Results of an F2-Study Database JCO JCO.2010.33.4474; published online on September 24, 2012

  7. Jacobson CA, Freedman AS (2012) Early stage follicular lymphoma, current management and controversies. Curr Opin Oncol 24(5):475–479

    Article  PubMed  Google Scholar 

  8. Press OW (1999) Review radiolabeled antibody therapy of B-cell lymphomas. Semin Oncol 26(5 Suppl 14):58–65

    CAS  PubMed  Google Scholar 

  9. Illidge T, Morschhauser F (2011) Radioimmunotherapy in follicular lymphoma. Best Pract Res 24(2):279–293

    Article  Google Scholar 

  10. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol 20(10):2453–2463

    Article  CAS  PubMed  Google Scholar 

  11. Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, D’Amore F, Gonzalez GM, Petrini M, Sebban C, Zinzani PL, van Oers MHJ, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A (2008) Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 26:5156–5164

    Article  CAS  PubMed  Google Scholar 

  12. Andrade Campos MM, Montes Limón AE, Grasa JM, Lievano P, Baringo T, Giraldo P. RIT with Y90-Ibritumomab Tiuxetan in follicular non-Hodgkin lymphoma: evaluation of recent outcomes in a single institution. J Oncol. 2012;2012:412742. Epub 2012 Sep 25

  13. Illdge TM (2010) Radioimmunotherapy of lymphomas: a treatment approach ahead of its time or past its sell by date? J Clin Oncol 28:2944–2946

    Article  Google Scholar 

  14. Tennvall J, Fischer M, Bischof Delaloye A et al (2007) EANM procedure guideline for radio-immunotheapy for B-cell lymphoma with 90Y-radiolabelled ibritumumab tiuxetan (Zevalin®). Eur J Nucl Med 48:1767–1776

    Article  Google Scholar 

  15. Jacene HA, Filice R, Kasecam W, Wahl R (2009) 18 F-DG PET/CT for monitoring the response of lymphoma to radioimmunotherapy. J Nucl Med 50:8–17

    Article  CAS  PubMed  Google Scholar 

  16. Pyo J, Kim KW, Jacene HA, Sakellis C, Brown J, Abbeele V d (2013) A end-therapy positron emission tomography for treatment response assesment in folicular lymphoma: a systematic review and meta-analysis. Clin Cancer Res 19:6566–6577

    Article  CAS  PubMed  Google Scholar 

  17. Aaronson NK, Acquadro C, Alonso J et al (1992) International quality of life assessment (IQOLA) project. Quall IFE rES 1:349–351

    CAS  Google Scholar 

  18. Alonso J, Prieto L, Antó JM (1995) La Version española del SF-36 health survey (Cuestionario de Salud SF-36): un instrumento para la medida de los resultados. Med Clin (Barc) 104:771–776

    CAS  Google Scholar 

  19. Costa-Requena G, Gil F. Quality of life in the chemotherapy treatment of Spanish cancer patients: a comparison of general population norms

  20. Herce-Lopez J, Rollon-Mayordomo A, Lozano-Rosado R, Infante-Cossio P, Salazar-Fernandez CI. Assessment of quality of life of oral cancer survivors compared with Spanish populations norms

  21. Lowry L, Ardeshna KM (2012) Has single-agent rituximab replaced watch-and-wait for patient with asymptomatic low-grade follicular lymphoma? Cancer J 18(5):390–395

    Article  CAS  PubMed  Google Scholar 

  22. Rose AC, Shenoy PJ, Garett G et al (2012) A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma. Clin Lymphoma Myeloma Leuk 12(6):393–399

    Article  PubMed  Google Scholar 

  23. Mourschhauser F, Radford J, Van Hoof A, et al.: 90Ytrium-Ibritumomab Tiuxetan Consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-Line Indolent Trial. J Clin Oncol 2013(Published ahead of print on April 1, 2013 JCO.2012.45.6400

  24. Hohloch K, Bischof Delaloye A, Windemuth-Kiesselbach C et al (2011) Radioimmunotherapy confers long-term survival to lymphoma patients with acceptable toxicity: registry analysis by the international radioimmunothrapy network. J Nucl Med 52:1354–1360

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was partially supported by a grant from FEHHA, and would not have been possible without the collaboration of the nursing staff in the Outpatient Clinic, and of the patients and their families.

Author information

Authors and Affiliations

  1. Department of Haematology, Miguel Servet University Hospital, Zaragoza, Spain

    Marcio Miguel Andrade-Campos, Anel E. Montes-Limón, Gloria Soro-Alcubierre, José María Grasa & Pilar Giraldo

  2. Contrato Rio Hortega, Traslational Research Unit, Miguel Servet University Hospital, Zaragoza, Spain

    Marcio Miguel Andrade-Campos & Pilar Giraldo

  3. CIBERER. ISCIII, Instituto Aragonés de Ciencias de la Salud (I+CS), Zaragoza, Spain

    Marcio Miguel Andrade-Campos & Pilar Giraldo

  4. Department of Haematology, Royo Villanova Hospital, Zaragoza, Spain

    Luis Lopez-Gómez

  5. Department of Nuclear Medicine, Miguel Servet University Hospital, Zaragoza, Spain

    Teresa Baringo

Authors
  1. Marcio Miguel Andrade-Campos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anel E. Montes-Limón
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gloria Soro-Alcubierre
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. José María Grasa
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luis Lopez-Gómez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Teresa Baringo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Pilar Giraldo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pilar Giraldo.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Andrade-Campos, M.M., Montes-Limón, A.E., Soro-Alcubierre, G. et al. Long-term efficacy of 90Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life. Ann Hematol 93, 1985–1992 (2014). https://doi.org/10.1007/s00277-014-2145-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2145-6

Keywords

Search

Navigation